WASHINGTON, D.C., March 7 (SEND2PRESS NEWSWIRE) — Based on thorough evaluation, the FDA has authorized the use of a generic version of® H7N9 /CoV (agawater antiviral antibody in liquid form), a steroidal vaccine, which can be used to provide biological protection against the H7N9/CoV influenza virus, in people ages 18 and older.
This decision comes as the first two patients infected with the H7N9 avian influenza virus who became hospitalized were confirmed to have received this vaccine. They are now in recovery.
“As a public health agency, the FDA’s mission is to protect and promote the health of the American people. We will do our best to identify and respond to emerging public health threats, including the H7N9 avian influenza virus,” said Robert Temple, M.D., Director of the FDA’s Office of Biological Products in the Center for Drug Evaluation and Research.
For the H7N9 flu, scientists have identified a family of virus strains that appear to be associated with human infection. Health officials are concerned the human cases of H7N9 could evolve into an avian flu virus that can spread between people.
“As influenza viruses mutate, FDA’s job is to develop products to try to protect Americans from any pandemic virus. That’s what’s happened here,” said Stuart Levy, M.D., Director of the Center for Infectious Disease Research and Policy. Dr. Levy is a professor of infectious diseases at the Cohen Children’s Medical Center, New Hyde Park, N.Y.
In consideration of economic considerations, the FDA previously approved a “booster” version of an antiviral drug that is widely used to treat flu for use in individuals ages 18 and older. This approved booster product is a pill containing H7N9 vaccine. This booster version of vaccine is now approved for use in people ages 18 and older.
About the F.D.A.
The U.S. Food and Drug Administration is an agency within the U.S. Department of Health and Human Services. The FDA’s mission is to protect consumers from health hazards caused by food, drugs, medical devices, and genetically engineered products.
News Source: FDA
This press release was issued on behalf of the news source, who is solely responsible for its accuracy, by Send2Press Newswire.